Theravance Biopharma (TBPH) Net Income towards Common Stockholders Growth (3y) (2016 - 2026)
Theravance Biopharma (TBPH) Net Income towards Common Stockholders Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 38.43% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 13.80% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -3.84% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 144.84% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Theravance Biopharma | 864.82 Mn | 470.15 Mn | - | 38.81% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 38.81% |
| Dec 31, 2025 | 94.49% |
| Sep 30, 2025 | -84.26% |
| Jun 30, 2025 | 43.96% |
| Mar 31, 2025 | -42.13% |
| Dec 31, 2024 | -37.55% |
| Sep 30, 2024 | -37.79% |
| Jun 30, 2024 | -49.29% |
| Mar 31, 2024 | -54.84% |
| Dec 31, 2023 | 58.69% |
| Sep 30, 2023 | 50.47% |
| Jun 30, 2023 | 37.11% |
| Mar 31, 2023 | 36.08% |
| Dec 31, 2022 | 27.23% |
| Sep 30, 2022 | 161.42% |
| Jun 30, 2022 | 35.02% |
| Mar 31, 2022 | 30.35% |
| Dec 31, 2021 | 35.98% |
| Sep 30, 2021 | 32.89% |
| Jun 30, 2021 | 32.10% |